pre-IPO PHARMA

COMPANY OVERVIEW

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases.


LOCATION

  • San Diego, CA, USA

  • THERAPEUTIC AREAS

  • Gastrointestinal Disease
  • Liver Disease

  • WEBSITE

    https://www.metacrine.com


    CAREER WEBSITE

    https://www.metacrine.com/careers/


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments arch-venture-partners arrowmark-partners deerfield-management ecor1-capital franklin-templton-investments invus lifesci-venture-partners lilly-asia-ventures nea polaris-partners venbio venrock vivo-capital


    PRESS RELEASES


    Mar 7, 2018

    Metacrine to Present at 30th Annual ROTH Conference and H.C. Wainwright & Co. 2nd Annual NASH Investor Conference


    Dec 7, 2017

    Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development


    Oct 10, 2017

    Metacrine's FXR Program to be Highlighted in Three Abstracts at The Liver Meeting® 2017 in Washington, D.C.


    Aug 15, 2017

    Metacrine Announces Collaboration on Development of FGF1 Variants for Glucose Lowering and Improving Insulin Sensitivity


    Apr 11, 2017

    Metacrine to Present Two Abstracts on its Novel FXR Non-Bile Acid Agonist Program at the EASL International Liver Congress 2017


    For More Press Releases


    Google Analytics Alternative